{
    "guideline": {
        "id": "PA166161954",
        "name": "Annotation of CPIC Guideline for ondansetron and CYP2D6",
        "source": "CPIC",
        "version": 32,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166161954",
        "relatedChemicals": [
            {
                "id": "PA450705",
                "name": "ondansetron",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA128",
                "name": "cytochrome P450 family 2 subfamily D member 6",
                "symbol": "CYP2D6"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166298294",
            "name": "Recommendation PA166298294",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060896,
                "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.</p>\n"
            },
            "implications": [
                "CYP2D6: Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.75"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298312",
            "name": "Recommendation PA166298312",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060914,
                "html": "<p>Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</p>\n"
            },
            "implications": [
                "CYP2D6: Very limited data available for CYP2D6 poor metabolizers"
            ],
            "lookupKey": {
                "CYP2D6": "0.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298303",
            "name": "Recommendation PA166298303",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060905,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</p>\n"
            },
            "implications": [
                "CYP2D6: Normal metabolism"
            ],
            "lookupKey": {
                "CYP2D6": "2.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298298",
            "name": "Recommendation PA166298298",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060900,
                "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.</p>\n"
            },
            "implications": [
                "CYP2D6: Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298307",
            "name": "Recommendation PA166298307",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060909,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</p>\n"
            },
            "implications": [
                "CYP2D6: Normal metabolism"
            ],
            "lookupKey": {
                "CYP2D6": "1.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298300",
            "name": "Recommendation PA166298300",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060902,
                "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.</p>\n"
            },
            "implications": [
                "CYP2D6: Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
            ],
            "lookupKey": {
                "CYP2D6": "2.75"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298295",
            "name": "Recommendation PA166298295",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060897,
                "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.</p>\n"
            },
            "implications": [
                "CYP2D6: Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298313",
            "name": "Recommendation PA166298313",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060915,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "CYP2D6: n/a"
            ],
            "lookupKey": {
                "CYP2D6": "n/a"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298308",
            "name": "Recommendation PA166298308",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060910,
                "html": "<p>Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</p>\n"
            },
            "implications": [
                "CYP2D6: Very limited data available for CYP2D6 intermediate metabolizers"
            ],
            "lookupKey": {
                "CYP2D6": "1.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298304",
            "name": "Recommendation PA166298304",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060906,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</p>\n"
            },
            "implications": [
                "CYP2D6: Normal metabolism"
            ],
            "lookupKey": {
                "CYP2D6": "2.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298299",
            "name": "Recommendation PA166298299",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060901,
                "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.</p>\n"
            },
            "implications": [
                "CYP2D6: Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
            ],
            "lookupKey": {
                "CYP2D6": "4.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298301",
            "name": "Recommendation PA166298301",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060903,
                "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.</p>\n"
            },
            "implications": [
                "CYP2D6: Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
            ],
            "lookupKey": {
                "CYP2D6": "3.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298296",
            "name": "Recommendation PA166298296",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060898,
                "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.</p>\n"
            },
            "implications": [
                "CYP2D6: Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298292",
            "name": "Recommendation PA166298292",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060894,
                "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.</p>\n"
            },
            "implications": [
                "CYP2D6: Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298310",
            "name": "Recommendation PA166298310",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060912,
                "html": "<p>Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</p>\n"
            },
            "implications": [
                "CYP2D6: Very limited data available for CYP2D6 intermediate metabolizers"
            ],
            "lookupKey": {
                "CYP2D6": "0.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298309",
            "name": "Recommendation PA166298309",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060911,
                "html": "<p>Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</p>\n"
            },
            "implications": [
                "CYP2D6: Very limited data available for CYP2D6 intermediate metabolizers"
            ],
            "lookupKey": {
                "CYP2D6": "0.75"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298305",
            "name": "Recommendation PA166298305",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060907,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</p>\n"
            },
            "implications": [
                "CYP2D6: Normal metabolism"
            ],
            "lookupKey": {
                "CYP2D6": "1.75"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298311",
            "name": "Recommendation PA166298311",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060913,
                "html": "<p>Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</p>\n"
            },
            "implications": [
                "CYP2D6: Very limited data available for CYP2D6 intermediate metabolizers"
            ],
            "lookupKey": {
                "CYP2D6": "0.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166301326",
            "name": "Recommendation Annotation PA166301326",
            "population": null,
            "classification": null,
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452095645,
                "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x\u22653</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x\u22653</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x\u22653</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x\u22653</strong> or <strong>*2x2 versus *2x\u22653</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x\u22653</td>\n<td>Increased</td>\n<td>\u22653</td>\n<td></td>\n<td></td>\n<td>\u22653</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
            },
            "implications": [],
            "lookupKey": {
                "CYP2D6": "xN combinations"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298302",
            "name": "Recommendation PA166298302",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060904,
                "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.</p>\n"
            },
            "implications": [
                "CYP2D6: Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
            ],
            "lookupKey": {
                "CYP2D6": "2.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298297",
            "name": "Recommendation PA166298297",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060899,
                "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.</p>\n"
            },
            "implications": [
                "CYP2D6: Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298293",
            "name": "Recommendation PA166298293",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060895,
                "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.</p>\n"
            },
            "implications": [
                "CYP2D6: Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298306",
            "name": "Recommendation PA166298306",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA450705",
                    "name": "ondansetron",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060908,
                "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</p>\n"
            },
            "implications": [
                "CYP2D6: Normal metabolism"
            ],
            "lookupKey": {
                "CYP2D6": "1.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        }
    ],
    "citations": [
        {
            "pmid": "28002639",
            "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.",
            "authors": [
                "Bell G C",
                "Caudle K E",
                "Whirl-Carrillo M",
                "Gordon R J",
                "Hikino K",
                "Prows C A",
                "Gaedigk A",
                "Agundez Jag",
                "Sadhasivam S",
                "Klein T E",
                "Schwab M"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2017
        }
    ],
    "version": "2024-03-25-16-13"
}